We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Abd Serotec Signs License Agreement with UCLB for Diagnostic Antibody

By LabMedica International staff writers
Posted on 24 Aug 2010
AbD Serotec (Martinsried, Germany) has signed an exclusive license agreement with UCL Business PL, (UCLB; London, UK). More...


AbD Serotec the research and diagnostic antibodies unit of MorphoSys AG (Martinsried/Munich, Germany), has reached an agreement with UCLB, the technology development company of University College London (UCL, London, UK) for access to a potent antiparathyroid hormone (PTH) antibody for diagnostic and research use.

The agreement provides AbD Serotec with worldwide exclusive access to a potent anti-PTH antibody, which forms the basis of an existing relationship between them and a leading diagnostic company, which markets clinical parathyroid hormone assays. PTH assays in other conditions provide clinicians with important information that assists in managing patients with abnormal calcium levels.

Parathyroid hormone is the most important regulator of calcium levels in the human body. When blood calcium becomes too low, calcium-sensing receptors in the parathyroid gland are activated and parathyroid hormone is secreted, thereby mobilizing calcium release from bone and suppressing calcium loss in urine.

Measurement of PTH is important in determining the cause of excessively high or low calcium levels. PTH assays are used as a routine clinical tool to detect decreases in plasma PTH levels after all diseased tissue has been excised, even while surgery is taking place. The test allows a more limited procedure by confirming complete removal of diseased tissue and it has reduced the need for repeated surgery.

Dieter Feger, head of AbD Serotec, said, "Our goal is to achieve a market-leading position in those areas we see as our sweet spots. In this particular case, the anti-PTH antibody sourced from our relationship with UCL has already allowed us to forge a first supply agreement with a leading diagnostic company. We have thus decided to expand this strong position and take an exclusive license for this product from UCLB."

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies.

Related Links:

AbD Serotec
UCL Business PL
MorphoSys AG
University College London



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.